drugset / Trial / NCT02874651
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Phase 2
Terminated
25 enrolled
Sun Yat-sen University
First People's Hospital of Foshan · collabGuilin Medical University, China · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. The purpose is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients treated with apatinib versus placebo (phase IIb).
Timeline
- Start
- 2016-10
- Primary completion
- 2018-11-29
- Completion
- 2020-08-27
Outcome
Outcome not reported
Stopped: “Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |